ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
The chart shows the growth of an initial investment of $10,000 in ANI Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
ANI Pharmaceuticals, Inc. (ANIP) has returned -6.18% so far this year and 14.91% over the past 12 months. Looking at the last ten years, ANIP has achieved an annualized return of 7.29%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of ANI Pharmaceuticals, Inc. (ANIP) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.48% | -9.71% | 3.92% | -4.01% | ||||||||
| 2025 | 5.47% | 6.97% | 9.95% | 5.53% | -17.11% | 11.16% | -2.31% | 48.13% | -2.14% | -1.05% | -6.26% | -6.25% |
| 2024 | 1.84% | 21.56% | 1.30% | -4.38% | -1.53% | -1.89% | 3.50% | -3.20% | -5.94% | -4.08% | -0.38% | -3.32% |
| 2023 | 9.50% | -6.86% | -8.01% | -4.19% | 19.61% | 19.46% | -1.81% | 23.05% | -9.98% | 7.08% | -19.02% | 11.15% |
| 2022 | -13.30% | -7.58% | -24.90% | 3.58% | 3.24% | -2.30% | 16.34% | 7.46% | -12.33% | 19.25% | 7.65% | -3.76% |
| 2021 | -0.38% | 2.46% | 21.44% | -7.91% | 2.45% | 0.69% | -2.33% | -10.82% | 9.00% | 13.76% | -3.11% | 9.95% |
| 2020 | -0.32% | -23.40% | -15.91% | -0.57% | -20.81% | 4.52% | -8.47% | 6.09% | -9.81% | -10.40% | 13.91% | -2.16% |
| 2019 | 20.98% | 22.67% | 6.75% | -0.13% | -1.89% | 18.00% | 1.92% | -22.67% | 11.99% | 7.66% | -21.45% | -0.26% |
| 2018 | 3.07% | -4.59% | -9.19% | 2.40% | 6.84% | 5.15% | 0.51% | -13.08% | -2.67% | -14.86% | 13.94% | -20.06% |
| 2017 | -0.46% | -2.12% | -16.86% | 8.92% | -19.52% | 7.04% | 4.10% | -1.94% | 8.65% | 10.06% | 22.60% | -9.16% |
| 2016 | 36.30% | 18.78% | 3.01% | 8.70% | -1.27% | 11.27% | -9.87% | -1.45% | 2.55% |
The charts below present risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ANIP compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current ANI Pharmaceuticals, Inc. volatility is 2.06%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.44B | 1.28B | 904.42M | 760.09M | 771.60M | 461.19M | 456.79M | 430.60M | 412.14M | 322.86M | 285.27M | 263.71M | 44.50M |
| Temporary Equity Attributable To Parent (USD) | - | 24.85M | 24.85M | 24.85M | 24.85M | - | - | - | - | - | - | - | - |
| Temporary Equity (USD) | - | 24.85M | 24.85M | 24.85M | 24.85M | - | - | - | - | - | - | - | - |
| Equity Attributable To Parent (USD) | 540.72M | 403.68M | 432.75M | 313.69M | 333.89M | 195.70M | 212.79M | 197.26M | 174.76M | 169.65M | 160.08M | 139.79M | 40.96M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 540.72M | 403.68M | 432.75M | 313.69M | 333.89M | 195.70M | 212.79M | 197.26M | 174.76M | 169.65M | 160.08M | 139.79M | 40.96M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | 69.95M | 625.00K | - | - | - |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | 128.21M | 120.64M | 113.43M | 110.69M | - |
| Noncurrent Liabilities (USD) | 621.54M | 661.49M | 301.35M | 322.11M | 325.32M | 186.93M | 182.32M | 67.79M | 198.15M | 121.27M | 113.43M | 110.69M | - |
| Other Current Liabilities (USD) | 177.63M | 110.30M | 85.01M | 59.82M | 56.05M | 61.07M | 43.33M | 153.14M | 33.29M | 26.93M | 8.50M | 9.23M | 2.11M |
| Wages (USD) | 37.90M | 37.73M | 23.79M | 10.31M | 8.52M | 6.23M | 3.74M | 3.52M | 2.31M | 1.63M | 1.19M | 1.35M | - |
| Accounts Payable (USD) | 62.58M | 45.66M | 36.68M | 29.31M | 22.97M | 11.26M | 14.61M | 8.88M | 3.63M | 3.39M | 2.07M | 2.65M | 1.43M |
| Current Liabilities (USD) | 278.11M | 193.68M | 145.48M | 99.44M | 87.54M | 78.57M | 61.68M | 165.55M | 39.23M | 31.95M | 11.76M | 13.23M | 3.54M |
| Liabilities (USD) | 899.65M | 855.17M | 446.82M | 421.55M | 412.86M | 265.49M | 244.00M | 233.34M | 237.38M | 153.22M | 125.18M | 123.92M | 3.54M |
| Other Non-current Assets (USD) | 145.26M | 157.32M | 131.00M | 120.95M | 103.03M | 61.09M | 48.16M | 38.03M | 30.34M | 33.07M | 19.15M | 12.94M | 1.84M |
| Intangible Assets (USD) | 479.53M | 541.83M | 209.01M | 251.64M | 294.12M | 188.51M | 180.39M | 201.60M | 229.79M | 175.79M | 66.40M | 42.07M | 10.41M |
| Fixed Assets (USD) | 62.48M | 56.86M | 44.59M | 43.25M | 52.67M | 41.27M | 40.55M | 38.09M | 20.40M | 11.00M | 7.13M | 5.22M | 4.54M |
| Noncurrent Assets (USD) | 687.26M | 756.01M | 384.61M | 415.83M | 449.82M | 290.87M | 269.09M | 277.73M | 280.53M | 219.86M | 92.68M | 60.23M | 16.78M |
| Other Current Assets (USD) | 586.86M | 372.93M | 391.22M | 230.52M | 232.49M | 103.66M | 135.54M | 107.85M | 91.09M | 73.26M | 177.74M | 193.98M | 23.62M |
| Prepaid Expenses (USD) | 23.19M | 17.98M | 17.40M | 8.39M | 7.59M | 5.86M | 4.00M | 4.52M | 2.78M | 3.56M | 1.45M | 1.98M | 580.00K |
| Inventory (USD) | 143.07M | 136.78M | 111.20M | 105.36M | 81.69M | 60.80M | 48.16M | 40.50M | 37.73M | 26.18M | 13.39M | 7.52M | 3.52M |
| Current Assets (USD) | 753.12M | 527.68M | 519.82M | 344.26M | 321.78M | 170.32M | 187.70M | 152.88M | 131.61M | 103.01M | 192.58M | 203.48M | 27.72M |
| Assets (USD) | 1.44B | 1.28B | 904.42M | 760.09M | 771.60M | 461.19M | 456.79M | 430.60M | 412.14M | 322.86M | 285.27M | 263.71M | 44.50M |
An ANI Pharmaceuticals executive sold 4,772 shares worth $357,471 on March 11, 2026, representing routine portfolio trimming rather than a bearish signal. The company reported record 2025 revenue of $883.4 million (up 43.8% YoY) driven by strong rare disease segment growth, with management guiding for over $1 billion in 2026 revenue.
ANI Pharmaceuticals announced it will release its fourth quarter and full year 2025 financial results on February 27, 2026, prior to market open. The company expects full year 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above guidance ranges. A conference call will be hosted by CEO Nikhil Lalwani and other executives to discuss the results.
Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather than a loss of confidence. ANI's future returns will depend on sustained rare disease growth and margin discipline rather than multiple expansion.
CG Oncology announced that its leadership will participate in two upcoming investor conferences in September 2025, presenting at the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference.
Cg Oncology reported a wider net loss in Q2 2025, with no revenue and increased R&D expenses. The company continues developing a gene therapy for bladder cancer and plans to submit a Biologics License Application in Q4 2025.
ANI Pharmaceuticals reported record quarterly net revenues of $197.1 million, a 43.4% year-over-year growth. The company's Rare Disease business generated $69.0 million in quarterly net revenues and presented preclinical data on the use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis mouse model.
ANI Pharmaceuticals reported strong Q4 results, with adjusted EPS and sales beating estimates. The company raised its 2025 guidance for revenue and adjusted EPS, driven by growth in its Cortrophin Gel, generics, and branded products.
ANI Pharmaceuticals, Inc. announced that it will release its third quarter 2024 financial results on November 8, 2024, and host a conference call to discuss the results.
Avadel Pharmaceuticals received FDA approval to expand the label of its narcolepsy drug Lumryz to include treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older. This expands the drug's indication to the pediatric population and is expected to boost sales.
Alnylam Pharmaceuticals has submitted a regulatory filing in the EU for its investigational drug vutrisiran to treat ATTR amyloidosis with cardiomyopathy. The filing is supported by positive results from a late-stage study, and if approved, the drug has the potential to become the new standard of care for ATTR-CM treatment.
